A proposed class action alleges Rexall Sundown, Inc. and Nature’s Bounty Company, Inc. falsely represent that their Osteo Bi-Flex supplement contains triple the dose of a joint relief extract. According to the case, the companies have “systematically underdosed” the products, which the plaintiff argues “simply do not work as advertised” to relieve pain or improve health.
Filed in New York, the lawsuit centers on the defendants’ alleged underdosing of 5-Loxin, or Boswellia serrata extract, in their Osteo Bi-Flex products. According to the case, the extract is clinically proven to ease the pain of swollen and stiff joints. The suit says the clinical study relied on by the defendants found that 250mg of the extract brought the best relief. Osteo Bi-Flex, however, contains just 100mg of the extract despite being advertising as a triple-strength dose. From the complaint:
“Defendants unlawfully save on the cost of ingredients, while shortchanging the consumers who are in the greatest physical discomfort (and thus seeking out an enhanced ‘triple strength’ product which they do not receive.)”
Notably, the lawsuit points out that the defendants were previously hit with a $2.1 million-dollar penalty by the FTC after falsely marketing that a children’s vitamin product contained 100mg of DHA when, in truth, it only had trace amounts of the fatty acid.